Kornimate/medical-research-clean huggingface dataset:
diagnosis and treatment of acute coronary syndrome in the ed & the impact of rapid bedside ctnl on outcome.

Conditions: Unstable Angina; Non-ST-Elevation Myocardial Infarction

Summary: the primary outcome in this study will be time to discharge for low-risk patients and therapeutic turnaround time for patients with nstemi or unstable angina.

phase iv prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. assess the reduction in time taken to dispostion or discharge patients. assess the ability of poc testing to satisfy guidelines for a 30 minute turn around time of results. assess and differences in clinical decision-making for other diagnostic procedures including nuclear imaging, echo, and stress treadmill, disposition from the ed, time to catherterization lab, pci, and cafbg based on the cardiac troponinn results from the bedside analyzer and the central lab instrument.assess the difference for in-hospital and 30 day post hospital discharge cardiac events including all-cause and cardiac-specific deaths, chf, cardiomyopathy, and atrial and ventricular arrhythmia, beween the bedside analyzer and the central lab instrument. assess the differences in hospital care costs for the hospitalization period, and assess direct medical and indirect productivity costs in the 30 day post hospital discharge period to patients who are diagnosed, using the bedside ctnl test and the central lab ctn tests, and subsequently treated as per the guidelines.

Eligibility criteria:
patient must be 21 years old or older with chest pain or other symptoms that lead to drawing cardiac biomarkers.
precision pain research registry

Conditions: Chronic Low Back Pain

Summary: the precision pain research registry enrolls participants with chronic low back pain (cases) and participants who are free of chronic pain (controls) to study the epidemiology and management of chronic pain. the vision of the registry is to conduct research to provide a future for all unbounded by pain.

case participants complete case report forms at quarterly encounters, whereas control participants complete a case report form only at an initial encounter. a series of validated or recommended research instruments are used or adapted by the registry for deployment in its case report forms. these may include some or all of the following at a given encounter: * national institutes of health minimum dataset for research on chronic low back pain * roland-morris disability questionnaire * patient-reported outcomes measurement information system (promis-29) * history of medical conditions inventory * pain sensitivity questionnaire * pain catastrophizing scale * pain self-efficacy questionnaire * non-pharmacological treatments inventory * pharmacological treatments summary * drug adverse events index * physician profile * physician communication behavior questionnaire * physician consultation and relational empathy measure * patient satisfaction questionnaire (psq-18) these instruments include measures that may serve as the independent or dependent variables in various substudies conducted by the registry over time, including observational studies (e.g., case-control studies, cohort studies) and randomized controlled trials. the registry also maintains a biobank of biological specimens that have been collected from enrolled participants, including saliva and blood that may be used for dna sequencing or biomarker analysis.

Eligibility criteria:
inclusion criteria: * must reside within the contiguous 48 united states or district of columbia * must provide a valid, government-issued identification with photo and birthdate * must have internet access or telephone service to communicate with registry staff * must have sufficient english language proficiency to complete case report forms independently or with assistance from registry staff * must have a primary care physician or other physician who regularly provides health care * must provide the name, dose, and frequency of use of all current medications * case participants must have chronic low back pain * control participants must be free of any chronic pain and may include healthy volunteers exclusion criteria: * must not be pregnant * must not reside in an institutional facility
a phase ii study by using cics-1 and spm-011 commissioned by cics and stella pharma

Conditions: Unresectable Angiosarcoma

Summary: the purpose of the study is to investigate efficacy and safety boron neutron capture therapy (bnct) by using cics-1 accelerator-based neutron capture therapy device with lithium targets developed by cics, and the spm-011 boron compound for use in bnct developed by stella pharma in the treatment of unresectable angiosarcoma.


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained from the subject. * histologically documented primary skin angiosarcoma. * locally advanced or locally recurrent angiosarcoma, and not eligible for curative surgery, chemoradiotherapy or radiotherapy. (including cases where the individual refuses treatment.) * measurable disease, as defined by recist v1.1. * the longest diameter of the entire target lesion is 15 cm or less. * ecog performance status score of grade 0 to 2 exclusion criteria: * apparent disseminated tumor lesions. * hereditary fructose intolerance. * phenylketonuria. * any serious concomitant disease that precludes completion of the study treatment. * the target lesion has received radiation exceeding 75 gy.
evaluation of morbidity and mortality associated with dysphagia in stroke patients based on pharyngeal residue severity

Conditions: Dysphagia Following Cerebral Infarction

Summary: specific objectives: * evaluation of morbidity and mortality associated with the severity of pharyngeal residue in patients admitted to hotêl-dieu de france university hospital for stroke based on the "the yale pharyngeal residue scale" * evaluation of the accuracy of screening protocol of dysphagia at the emergency department in patients admitted for stoke based on the "emergency department dysphagia screening tool"

dysphagia after stroke is common, affecting 27% to 64% of patients. complications of dysphagia include aspiration leading to chest infection and pneumonia, malnutrition, inability to rehabilitate, increased risk of infection, prolonged length of stay in hospital, and an increased risk of death. deglutologists who use fees have long lamented the fact that there was no reliable, validated, anatomically defined, image-based, and easily used pharyngeal residue severity rating scale. all that one had to rely on was the "impression" of residue severity, the definition of which varied from endoscopist to endoscopist in order for any scale to gain widespread acceptance, it must be user friendly, easy to learn, reliable to interpret, and generalizable to all patients undergoing fees. such a scale now exists, and it is the yale pharyngeal residue severity rating scale need for a trial: the relation between the severity of the pharyngeal residue and the risk of aspiration and subsequently the morbidity and mortality in stroke patients is not well defined yet. thus, the purpose of this study was to determine the morbidity and mortality associated with the severity of pharyngeal residue in a specific population: stroke patients another objective of the study is to evaluate the accuracy of emergency department (ed) dysphagia screening in stroke patients compared to a standard swallowing evaluation with fees. all patients admitted to hotêl-dieu de france university hospital for stroke will be evaluated for dysphagia using the ed dysphagia-screening tool. preliminary data on the accuracy of the "ed dysphagia screening tool" are promising (sensitivity of 96%) in this study outcomes between 2 groups will be evaluated; (ed failed screening group and ed screening passed group) and thus be able to validate results of previous studies concerning sensitivity and accuracy of the screening tool mentioned previously and finally to be able to identify stroke patients eligible for early oral nutrition.

Eligibility criteria:
inclusion criteria: * age \>18 years * patients admitted for stroke (ischemic or hemorragic) * patients reachable by phone call exclusion criteria: * previous history of major head and neck surgery * previous or actual history of treatment by chemotherapy or radiotherapy for a head and neck neoplasm * current head and neck neoplasm * previous or current history of esophageal carcinoma * esophageal motility disorder

Keywords: dysphagia pharyngeal residue scale stroke pneumonia
safety and tolerability study of rn6g in patients with dry, age-related macular degeneration

Conditions: Age-Related Maculopathy; Age-Related Maculopathies; Eye Diseases; Retinal Degeneration; Macular Degeneration

Summary: the purpose of this study is to determine the safety and tolerability of rn6g in patients with dry, age-related macular degeneration.


Eligibility criteria:
inclusion criteria: * be of non-childbearing potential. * diagnosis of dry amd as defined by the age-related eye disease study (areds, 2005), including uni- or multi-focal ga, without foveal involvement. * bcva of 20/320 or better in the worst eye. exclusion criteria: * diagnosis of exudative (wet) amd, with subretinal or choroidal neovascular lesions. * diagnosis or history of alzheimer's disease, dementia or neurodegenerative disorders. * diagnosis or recent history of clinically significant cerebrovascular disease. * uncontrolled hypertension. * uncontrolled type 1 or type 2 diabetes mellitus.

Keywords: phase 1 dry age related macular degeneration rn6g
personalized prevention of depression in the workplace (e-pd-work)

Conditions: Depression

Summary: the main goal is to design, develop and evaluate a personalized intervention to prevent depression in the workplace, based on information and communication technologies (icts), predictive risk algorithms and decision support systems (dss) for employed workers. the specific goals are: 1) to design and develop a dss, called e-predictd-work-dss to elaborate personalized plans to prevent depression and its monitoring in the employed working population; 2) to design and develop an ict solution that integrates the dss on the web, a mobile application (app), the predictd risk algorithm, different intervention modules (including a work stress management module) and a monitoring-feedback system; 3) to evaluate the usability, adherence, acceptability and satisfaction of employed working population with the e-pd-work intervention; 4) to evaluate the effectiveness of the e-pd-work intervention to reduce the incidence of major depression, depression and anxiety symptoms, the probability of major depression next year and to improve quality of life; 5) to evaluate the cost-effectiveness and cost-utility of the e-pd-work intervention to prevent depression. methods: this a randomized, double-blind, controlled trial with two parallel arms (e-pd-work vs active m-health control) and 12 months follow-up. a total of 3,160 depression-free workers, aged between 18 and 55 years old will be recruited in spain and randomly assigned to one of the two groups in a 1:1 ratio considering a stratification of age (18-29, 30-39, 40-49, 50-55 years) and sex similar to the spanish population. participants, interviewers and statisticians will be blinded to participants' allocation. the e-pd-work intervention is self-guided, has a biopsychosocial approach and is multi-component (9 modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress). the e-pd-work intervention will be implemented in the smartphone of the workers and pivot on an already validated risk predictive algorithm and a dss that helps workers to develop their own personalized depression prevention plans. primary outcome will be the rate of major depression measured by cidi. as secondary outcomes: depressive and anxiety symptomatology measured by phq-9 and gad-7 respectively, the risk probability of depression measured by the predictd risk algorithm, quality of life measured by sf-12 and euroqol, and cost-effectiveness and cost-utility.


Eligibility criteria:
inclusion criteria: * have a paid employement * phq-9 \<10 at baseline exclusion criteria: * not have a smartphone and internet for personal use * sick leave for more than 1 month * unable to speak spanish * documented terminal illness * documented cognitive impairment * documented serious mental illness (psychosis, bipolar, addictions, etc.)

Keywords: depression primary prevention randomized controlled trial m-health app workers
universal car-t cell therapy for refractory lupus nephritis

Conditions: Lupus Nephritis

Summary: this investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal car-t cells targeting bcma and cd19 in refractory lupus nephritis.

this study is a non-randomized, open-label, single-arm clinical trial designed to assess the efficacy and safety of combination therapy for refractory lupus nephritis using universal car-t cells targeting bcma and cd19.

Eligibility criteria:
inclusion criteria: * aged 18-65 years; both genders eligible. * subjects diagnosed with lupus nephritis. * previous treatment outcomes were unsatisfactory. * diagnosis of active nephritis type iii or iv with or without type v according to 2018 international society of nephrology and society of renal pathology (isn/rps) criteria. * nih activity index \> 2 and elevated chronicity index. * urine protein: creatinine ratio (upcr) ≥ 1.0 g/g, or 24-hour urine protein ≥ 1.0 g, with or without active urine sediment with red blood cell casts. * receiving hormones with or without antimalarials. * sledai-2k score ≥ 6. * antinuclear antibody positive, and/or anti-ds-dna antibody positive, and/or anti-smith antibody positive. * positive expression of cd19 on b cells in peripheral blood. * agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication. * provides written informed consent. exclusion criteria: * history of solid organ transplantation. * malignant tumor within the last two years. * positive for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab), with peripheral blood hepatitis b virus (hbv) dna detected as positive; positive for hepatitis c virus antibodies, with peripheral blood hepatitis c virus rna detected as positive; positive for human immunodeficiency virus (hiv) antibodies; positive for cytomegalovirus (cmv) dna; positive for syphilis. * primary immunodeficiency (congenital or acquired). * severe cardiac disease. * history of psychiatric disorders or history of psychotropic drug abuse, with no history of withdrawal. * allergic constitution or a history of severe allergies. * pregnant or breastfeeding women.
accelerating post-exercise muscle glycogen resynthesis in humans: impact of combined nutrient intake and intermittent pneumatic compression or heat therapy

Conditions: Muscle Recovery; Muscle Soreness; Glycogen Depletion

Summary: to determine if modalities designed to improve blood flow combined with post-exercise nutrient intake will improve replenishment of muscle glycogen better than nutrient intake alone. a secondary objective is to compare the effectiveness of heat therapy and intermittent pneumatic compression on glycogen replenishment.


Eligibility criteria:
inclusion criteria: 1. subjects will be male and female participants in good health 2. 18-35 years of age 3. currently performing cardiovascular or intermittent exercise at a moderate to high intensity at least 5 days per week for 60 minutes or longer per day. 4. understanding of the procedures to be undertaken as part of the study 5. willingness to participate in exercise testing and follow instructions provided by the experimenter 6. informed, voluntary, written consent to participate in the study exclusion criteria: 1. history of deep vein thrombosis 2. obesity (bmi \> 30 kg/m2) 3. hypertension (resting sbp \> 140/90 mmhg) 4. smoking 5. pregnant, planning to become pregnant, or lactating 6. supplements containing antioxidants including vitamin c and e and n-acetyl cysteine 7. any medication 8. lactose intolerance 9. participation in another study within the previous 30 days or in a pepsico funded study within the past 6 months.

Keywords: muscle glycogen glycogen replenishment muscle recovery intermittent pneumatic compression ipc heat therapy
he purongo mo nga kai hei arai i te matehuka - dietary diabetes prevention study for maori

Conditions: Insulin Resistance

Summary: high protein diets are popular among maori, especially on the east coast of the north island. the purpose of this study was to compare the metabolic effects of a moderate carbohydrate, high protein diet (mchp) with a high carbohydrate-high fibre (hchf) diet on insulin sensitivity in maori at increased risk of developing diabetes and cardiovascular disease.

this was a 6-month pilot intervention study of self-identifying maori participants in a randomised control trial conducted in dunedin and invercargill. the study consisted of three, two month phases and was conducted over a period of six months. participants meeting all the inclusion criteria were randomised into three groups: moderate carbohydrate-high protein (mchp), high carbohydrate-high fibre (hchf) or a control group. those randomised to the experimental diets were recommended an energy intake based on their current bmi levels. the aim of phase one was to achieve weight loss with weekly advice and support from the research team. the aim of phase two was for weight maintenance with continued weekly advice and support. phase three consisted of a weight maintenance phase without support. those in the control group were instructed to follow their own self selected diet plan. outcome was determined by examining surrogate clinical endpoints. the clinical endpoints included the following recorded measurements of anthropometric measurements, bioelectrical impedance measurements, profile of mood state questionnaires, activity questionnaires, and three day diet records were collected at 0, 2, 4 and 6 month periods. biochemical measures of lipid profile, fasting insulin and glucose, liver functions and uric acid levels were also conducted.

Eligibility criteria:
inclusion criteria: * self identify as maori aged between 17-75 years * male and female * non-diabetic * resident of dunedin and invercargill * bmi \>27 * family history of t2d exclusion criteria: * the presence of diabetes, renal or liver failure, or any other medical condition which is unstable and for which potential partcipants are currently having active treatment.

Keywords: maori insulin sensitivity cardiovascular risk diabetes prevention diet modification
improving followup of abnormal colon cancer screening tests

Conditions: Colorectal Cancer

Summary: the purpose of this study is to determine whether direct mailings to patients with positive fecal occult blood tests can increase rates of performing followup colonoscopy.

screening programs using the fecal occult blood test (fobt) have demonstrated a significant reduction in colorectal cancer mortality, although only when accompanied by a complete diagnostic evaluation of the colon in the setting of a positive result. 90% of patients with a positive fobt result have completed a subsequent colonoscopy within harvard vanguard medical associates. this project will use a pre-post study design to increase the rate of followup colonoscopy in the setting of positive fobt results. patients in the intervention group will receive a personalized mailing highlighting their positive result and need for colonoscopy, followed by telephone outreach from a centralized gastroenterology scheduling office. the primary outcome will be the performance of colonoscopy, however we will also perform chart reviews to identify predictors of completing appropriate followup.

Eligibility criteria:
inclusion criteria: * patients with positive fecal occult blood test during 2004, 2005, and 2006; and no colonoscopy following this test result exclusion criteria: * patients with active cardiopulmonary disease or limited life expectancy due to severe illness such as malignancy * colonoscopy within 5 years prior to positive fecal occult blood test * age \> 80 years

Keywords: colorectal cancer fecal occult blood test abnormal test result missed diagnosis delayed diagnosis
the effect and the pharmacogenomics study of liraglutide in obese patients

Conditions: Obesity

Summary: this studay evaluates the effect of liraglutide in the treatment of obese patients ande the influence of genetic factors on the curative effect.half of participants will receive liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive liraglutide and metformin in combination.

background:the rapid growth of obese or overweight people in the world has become a major social problem. obese often associated with kinds of metabolic disorders, especially type 2 diabetes, and liraglutide can effectively reduce weight and improve blood glucose.previous studies have indicated that most patients will experience different degrees of weight loss after using liraglutide, but there is also a small number of patients with no significant weight loss.the gene polymorphism among individuals may affect the weight loss effect of liraglutide. objectives：1.to find the relationships between genetic variants and the response of liraglutide to treatment of obese patients.2.to investigate the effects of liraglutide on weight, metabolism (blood glucose, blood lipid, uric acid, etc.) and gut microbiota in obese chinese patients. intervention:half of participants will receive liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive liraglutide and metformin in combination.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 65 years (to the date of screening)； 2. the newly diagnosed obese patients (bmi greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm). 3. nearly a month have not used weight-related drugs,including various weight-loss drugs,glp-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial. 4. weight stable for more than 3 months (weight fluctuations \<5%). exclusion criteria: 1. pregnant female. 2. secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others. 3. severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis. 4. combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes. 5. nearly a month had surgery, trauma, infection and so on. 6. limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators. 7. poor medication compliance or serious side effects (severe rash, syncope, etc.).